Recent news on Diclofenac Potassium

Migraine market: Trexima approval delays benefits generic triptan  -  Mar 29, 2007
Pharmaceutical Business Review...utilizing their proprietary delivery systems, whilst ProEthic is developing diclofenac potassium (PRO-513), a reformulation of diclofenac.

APR Announces Today Successful Phase Iii Clinical Trial Results ...  -  Jan 9, 2007
PharmaLive.com (press release),...double-blind, placebo-controlled trial that enrolled 690 adult patients, PRO-513, a proprietary formulation of diclofenac potassium powder for oral

ProEthic Pharmaceuticals Announces Positive Phase III Clinical ...  -  Jan 9, 2007
PipelineReview.com (press release),PRO-513 utilizes ProEthic’s patented Dynamic Buffering Technology (DBT), which enhances the absorption of its active ingredient, diclofenac potassium.

ProEthic Pharmaceuticals Announces Positive Phase I Trial Results ...  Aug 17, 2006
PRO-571 is a unique, rapid-release formulation of diclofenac potassium in tablet form, which utilizes ProEthic's Dynamic Buffering Technology (DBT). ... -International News Service

ProEthic cheered by positive pain drug trials  Aug 18, 2006
PRO-571 is a unique, rapid-release formulation of diclofenac potassium in tablet form, which utilizes ProEthic's Dynamic Buffering Technology (DBT). ... -Pharmaceutical Business Review

ProEthic reports significant progress on fast-acting pain reliever  Aug 17, 2006
Called PRO-571, the tablet is a "unique, rapid-release formulation of diclofenac potassium," Montgomery-based ProEthic states in a news release. ... -Birmingham Business Journal

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional